公开(公告)号：WO2005113536A2

公开(公告)日：2005-12-01

申请号：PCT/US2005/014866

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES ,  ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

IPC: C07D401/00

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds of formula (I) wherein R 1 or R 2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, X, X', Y, Y', Z, and Z' are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 式（I）化合物其中R 1或R 2是三环或双环，其各自含有至少两个杂原子，R 1，R 2，R 3，R 3a，R 3b，R 4，R 5，L，X，X'，Y， Y'，Z和Z'如本文所定义，可用于治疗由组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。

公开(公告)号：WO2008011337A1

公开(公告)日：2008-01-24

申请号：PCT/US2007/073422

申请日：2007-07-13

Applicant: ABBOTT LABORATORIES ,  WAGNER, Rolf ,  DONNER, Pamela L. ,  KEMPF, Dale J. ,  MARING, Clarence J. ,  STOLL, Vincent S. ,  KU, Yi-yin ,  PU, Yu-ming

Inventor： WAGNER, Rolf ,  DONNER, Pamela L. ,  KEMPF, Dale J. ,  MARING, Clarence J. ,  STOLL, Vincent S. ,  KU, Yi-yin ,  PU, Yu-ming

IPC: C07D495/04 ,  A61K31/505 ,  A61P31/12

CPC classification number: C07D495/04

Abstract: The present invention provides HCV polymerase inhibiting compounds having the formula (I) where R 1 is cyclobutyl-N(R a )-, n is 1, 2, 3 or 4, and at least one R 5 is R a SO 2 N(R j )alkyl-. In a non-limiting example, a compound of the present invention is N-[(3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl}-1,1-dioxo-1,4-dihydro-1?λ 6 -thieno[2,3-e][1,2,4]thiadiazin-7-yl)meth yl]methane-sulfonamide. The present invention also features compositions comprising the compounds of the present invention or pharmaceutically acceptable salts, stereoisomers or tautomers thereof, and methods of using the same to treat or prevent HCV infection.

Abstract translation: 本发明提供具有式（I）的HCV聚合酶抑制化合物，其中R 1是

公开(公告)号：WO2005113551A1

公开(公告)日：2005-12-01

申请号：PCT/US2005/014863

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES ,  ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

IPC: C07D417/14

CPC classification number: C07D215/12 ,  C07D401/04 ,  C07D401/08 ,  C07D401/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Compounds of formula (I) wherein R 1 or R 2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L 2 and L 3 , to a heteroaromatic core, and X, X', Y, Y', Z, Z', R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, L 2 , and L 3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 式（I）的化合物，其中R 1或R 2是通过由L 2和L 3表示的连接基直接连接或连接到杂芳族核心上的芳族或非芳族环，X，X'，Y，Y'，Z ，Z'，R1，R2，R3，R3a，R3b，R4，R5，L，L2和L3如本文所定义，可用于治疗组胺3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。

公开(公告)号：WO2004043458A1

公开(公告)日：2004-05-27

申请号：PCT/US2003/035365

申请日：2003-11-05

Applicant: ABBOTT LABORATORIES

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-Jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-Yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  SHARMA, Padam, N. ,  BENNANI, Youssef, L. ,  CURTIS, Michael, P.

IPC: A61K31/40

CPC classification number: C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/088 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 式（I）化合物可用于治疗由组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。

公开(公告)号：EP1751130A2

公开(公告)日：2007-02-14

申请号：EP05763655.7

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

IPC: C07D401/00

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds of formula (I) wherein R1 or R2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R1, R2, R3, R3a, R3b, R4, R5, L, X, X', Y, Y', Z, and Z' are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

公开(公告)号：EP1751149A1

公开(公告)日：2007-02-14

申请号：EP05743943.2

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

IPC: C07D417/14 ,  C07D401/04 ,  C07D417/04 ,  C07D413/04 ,  C07D409/14 ,  C07D413/14 ,  C07D215/12 ,  C07D401/14 ,  A61K31/4709 ,  A61P25/28 ,  A61P25/00

CPC classification number: C07D215/12 ,  C07D401/04 ,  C07D401/08 ,  C07D401/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X', Y, Y', Z, Z', R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

公开(公告)号：EP1751149B1

公开(公告)日：2012-06-06

申请号：EP05743943.2

申请日：2005-04-29

Applicant: Abbott Laboratories

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A. ,  KU, Yi-yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  CURTIS, Michael, P.

IPC: C07D401/08 ,  C07D417/14 ,  C07D401/04 ,  C07D417/04 ,  C07D413/04 ,  C07D409/14 ,  C07D215/12 ,  C07D401/14 ,  A61K31/4709 ,  A61P25/28 ,  A61P25/00 ,  C07D413/14

CPC classification number: C07D215/12 ,  C07D401/04 ,  C07D401/08 ,  C07D401/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X', Y, Y', Z, Z', R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

公开(公告)号：EP1569637A1

公开(公告)日：2005-09-07

申请号：EP03768721.7

申请日：2003-11-05

Applicant: ABBOTT LABORATORIES

Inventor： ALTENBACH, Robert, J. ,  BLACK, Lawrence, A. ,  CHANG, Sou-Jen ,  COWART, Marlon, D. ,  FAGHIH, Ramin ,  GFESSER, Gregory, A.; ,  KU, Yi-Yin ,  LIU, Huaqing ,  LUKIN, Kirill, A. ,  NERSESIAN, Diana, L. ,  PU, Yu-ming ,  SHARMA, Padam, N. ,  BENNANI, Youssef, L. ,  CURTIS, Michael, P.

IPC: A61K31/40 ,  C07D295/155 ,  C07D295/116 ,  A61P25/00 ,  A61P3/00 ,  C07D261/08 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07C255/58 ,  C07D295/088 ,  C07D207/20 ,  C07D215/12 ,  C07D215/14 ,  C07D217/14

CPC classification number: C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/088 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).